Eledon Pharmaceuticals: Promising Kidney Transplant Program and Strong Financial Position Support Buy Rating
I'm PortAI, I can summarize articles.
LifeSci Capital's Rami Katkhuda maintains a Buy rating on Eledon Pharmaceuticals, citing promising kidney transplant program developments and a strong financial position. The Phase II BESTOW study showed tegoprubart's differentiated safety profile, despite not achieving eGFR superiority. Eledon has $93.4 million in cash and plans a Phase III study in 2026. Noble Financial also reiterated a Buy rating with a $10.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments